Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity

Khadija Khan(Africa Health Research Institute), Farina Karim(Africa Health Research Institute), Yashica Ganga(Africa Health Research Institute), Mallory Bernstein(Africa Health Research Institute), Zesuliwe Jule(Africa Health Research Institute), Kajal Reedoy(Africa Health Research Institute), Sandile Cele(Africa Health Research Institute), Gila Lustig(Centre for the AIDS Programme of Research in South Africa), Daniel G. Amoako(National Health Laboratory Service), Nicole Wolter(National Health Laboratory Service), Natasha Samsunder(Centre for the AIDS Programme of Research in South Africa), Aida Sivro(Centre for the AIDS Programme of Research in South Africa), James Emmanuel San, Jennifer Giandhari, Houriiyah Tegally(Stellenbosch University), Sureshnee Pillay, Yeshnee Naidoo, Matilda Mazibuko(Africa Health Research Institute), Yoliswa Miya(Africa Health Research Institute), Nokuthula Ngcobo(Africa Health Research Institute), Nithendra Manickchund(University of KwaZulu-Natal), Nombulelo Magula(University of KwaZulu-Natal), Quarraisha Abdool Karim(Centre for the AIDS Programme of Research in South Africa), Anne von Gottberg(National Health Laboratory Service), Salim S. Abdool Karim(Centre for the AIDS Programme of Research in South Africa), Willem A. Hanekom(Africa Health Research Institute), Bernadett I. Gosnell(University of KwaZulu-Natal), COMMIT-KZN Team, Richard Lessells(University of Washington), Túlio de Oliveira(University of Washington), Mahomed‐Yunus S. Moosa(Centre for the AIDS Programme of Research in South Africa), Alex Sigal(Centre for the AIDS Programme of Research in South Africa)
medRxiv
May 1, 2022
Cited by 86Open Access
Full Text

Abstract

The SARS-CoV-2 Omicron (B.1.1.529) variant first emerged as the BA.1 sub-lineage, with extensive escape from neutralizing immunity elicited by previous infection with other variants, vaccines, or combinations of both 1,2 . Two new sub-lineages, BA.4 and BA.5, are now emerging in South Africa with changes relative to BA.1, including L452R and F486V mutations in the spike receptor binding domain. We isolated live BA.4 and BA.5 viruses and tested them against neutralizing immunity elicited to BA.1 infection in participants who were Omicron/BA.1 infected but unvaccinated (n=24) and participants vaccinated with Pfizer BNT162b2 or Johnson and Johnson Ad26.CoV.2S with breakthrough Omicron/BA.1 infection (n=15). In unvaccinated individuals, FRNT 50 , the inverse of the dilution for 50% neutralization, declined from 275 for BA.1 to 36 for BA.4 and 37 for BA.5, a 7.6 and 7.5-fold drop, respectively. In vaccinated BA.1 breakthroughs, FRNT 50 declined from 507 for BA.1 to 158 for BA.4 (3.2-fold) and 198 for BA.5 (2.6-fold). Absolute BA.4 and BA.5 neutralization levels were about 5-fold higher in this group versus unvaccinated BA.1 infected participants. The observed escape of BA.4 and BA.5 from BA.1 elicited immunity is more moderate than of BA.1 against previous immunity 1,3 . However, the low absolute neutralization levels for BA.4 and BA.5, particularly in the unvaccinated group, are unlikely to protect well against symptomatic infection 4 .This may indicate that, based on neutralization escape, BA.4 and BA.5 have potential to result in a new infection wave.


Related Papers

No related papers found

Powered by citation graph analysis